Stock GALA BIOP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company GALA BIOP Nasdaq

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for GALA BIOP
Jul. 08 Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation MT
Jul. 08 SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia CI

Business Summary

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Managers

Managers TitleAgeSince
Angelos Stergiou FOU
 Founder 48 06-04-02
John Burns DFI
 Director of Finance/CFO 39 13-04-30
Andrew Elnatan LAW
 General Counsel - 23-01-04
Dragan Cicic PRN
 Corporate Officer/Principal 60 20-02-09

Members of the board

Members of the board TitleAgeSince
Robert van Nostrand BRD
 Director/Board Member 67 17-12-28
David Scheinberg BRD
 Director/Board Member 68 17-11-30
John Varian BRD
 Director/Board Member 64 17-12-28
Jane Wasman CHM
 Chairman 67 17-12-28
Angelos Stergiou FOU
 Founder 48 06-04-02
Katherine Kalin BRD
 Director/Board Member 61 22-08-12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 57,754,928 57,598,688 ( 99.73 %) 0 99.73 %

Shareholders

NameEquities%Valuation
Anson Funds Management LP
8.367 %
4,832,368 8.367 % 6 M $
Vanguard Global Advisers LLC
2.620 %
1,513,235 2.620 % 2 M $
Geode Capital Management LLC
0.4728 %
273,063 0.4728 % 324 945 $
BlackRock Institutional Trust Co. NA
0.4726 %
272,966 0.4726 % 324 830 $
Opus Capital Group LLC
0.3473 %
200,600 0.3473 % 238 714 $
Equitable Advisors LLC
0.3463 %
200,000 0.3463 % 238 000 $
Dragan Cicic
0.2053 %
118,584 0.2053 % 141 115 $
STATE STREET CORPORATION
0.1682 %
97,129 0.1682 % 115 584 $
Northern Trust Investments, Inc.(Investment Management)
0.1535 %
88,680 0.1535 % 105 529 $
Angelos Stergiou
0.0987 %
56,984 0.0987 % 67 811 $

Company contact information

SELLAS Life Sciences Group, Inc.

Times Square Tower 7 Times Square

10026, New York

+

http://www.sellaslifesciences.com
address GALA BIOP

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.60% 127B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+22.58% 116B
ARGENX SE Stock argenx SE
+25.15% 27.69B
BIONTECH SE Stock BioNTech SE
-19.23% 19.62B
GENMAB A/S Stock Genmab A/S
-16.57% 16.26B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.96% 15.49B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.09% 14.81B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.65% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+56.34% 14.11B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SLS Stock
  4. Stock
  5. Company GALA BIOP